Skip to main content
TipRanks
Go Ultimate75% OFF

Alphatec Holdings (ATEC) Q3 2026 Earnings Report

966 Followers

ATEC Q3 2026 EPS Results

Actual EPS
$0.09
Consensus EPS
$0.10
Beat/Miss
Missed by -$0.01
One Year Ago EPS
$0.03

ATEC Q3 2026 Revenue Results

Actual Revenue
$221.17M
Expected Revenue
$225.16M
Beat/Miss
Missed by -$3.98M
YoY Revenue Growth
+12.55%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/29/2026
Time
After Close
Conference Call
Thursday, October 29, 2026
ATEC Upcoming Earnings

Alphatec Holdings's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

ATEC Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 29, 2026|% Change Since:-37.91%|
Earnings Call Sentiment|Neutral

The call presented strong underlying operating momentum, including 13% revenue growth, 20% procedural volume growth, approximately 25% surgeon adoption growth, significant EBITDA and margin expansion, positive free cash flow, and continued progress in Valence and EOS Insight. However, the quarter was described as frustrating because revenue missed expectations, biologics revenue declined, revenue per case fell 5%, thoracolumbar volumes were soft, EOS revenue was flat year-over-year, international supply issues affected adoption, and full-year revenue and free cash flow guidance were reduced. The positive operating and strategic developments were balanced by meaningful execution and market challenges.

Company Guidance

The company lowered full year 2026 total company revenue expectations to approximately $862 million, representing growth of roughly 13%, including surgical revenue of approximately $789 million, representing growth of approximately 15%, and EOS revenue of approximately $73 million; the outlook includes high-teens surgical case volume growth, a 3% decline in revenue per case, $102 million of year-over-year surgical dollar growth, 17% surgical hardware revenue growth and flat biologics revenue contribution year-over-year, with a temporary international supply constraint expected to impact international sales by about $3 million for the year and resolve as we enter 2027. Adjusted EBITDA is expected to be approximately $137 million, or a 16% margin, representing growth of approximately 47% year-over-year, and free cash flow is expected to be $10 million, implying approximately $15 million in the fourth quarter; the fourth-quarter guide implies an 18% EBITDA ratio, about $12 million associated with surgical volume and $4 million with EOS, with the surgical reduction approximately evenly split between lower biologics expectation and lower procedural volumes, or about $6 million and $6 million.

  • Strong Third-Quarter Revenue and Surgical GrowthQ3 revenue reached $221 million, up 13% year-over-year. Surgical revenue increased 14% to $202 million, while surgical hardware revenue grew 17%.
  • Surgeon Adoption and Procedure Volumes Remained StrongSurgical volumes grew approximately 20%, new surgeon growth increased approximately 25%, and ATEC attracted more new surgeons in Q3 than ever before. Management said these indicators reinforce confidence in the foundation and future growth of the platform.
  • Hardware Drove Surgical GrowthHardware revenue increased approximately $26 million and drove all surgical growth for the quarter, while biologics declined year-over-year. Management said surgical hardware growth has been consistent for years.
  • Cervical Volume Strength Offset Thoracolumbar WeaknessStrong cervical procedure volumes partially offset slower thoracolumbar volumes, resulting in total procedure volume growth of 20%. Management said ATEC continues to grow at multiples of the market, including in thoracolumbar procedures.
  • Adjusted EBITDA and Margin ExpansionAdjusted EBITDA reached $38 million, up approximately 46% or $12 million year-over-year. The adjusted EBITDA margin was 17%, expanding more than 400 basis points year-over-year.
  • Gross Margin and Operating Discipline ImprovedGross margin was 72%, up nearly 200 basis points year-over-year, supported by improved inventory efficiency, lower costs, and mix benefits from lower biologics attachment rates. Operating expenses grew approximately 8% year-over-year but improved approximately 260 basis points as a percentage of revenue.
  • Positive Free Cash Flow and LiquidityATEC generated approximately $6 million of positive free cash flow in Q3 and delivered positive trailing 12-month free cash flow for the fifth consecutive quarter. The company ended the quarter with approximately $80 million in cash and $55 million of available borrowing capacity, or roughly $135 million of total liquidity.
  • Balance Sheet SimplificationThe company repaid the remaining balance of its 2026 convertible notes with cash on hand, which management said simplified the capital structure, strengthened the balance sheet, and provided flexibility to continue growing and scaling the business.
  • Investment in Inventory and Instrument SetsATEC generated $34 million of operating cash flow during the quarter while investing $29 million in inventory and instrument sets to support its growing surgeon base and fourth-quarter needs.
  • EOS Insight Adoption and Strategic ValueEOS revenue was $20 million in Q3, up from $17 million in Q2. Management said established ATEC surgeon customers generate higher implant revenues after EOS Insight goes live and described Insight as a meaningful contributor to procedural adoption and long-term growth.
  • Broad EOS Academic Institution PresenceEOSedge is now present in more than 70% of academic institutions with fellowship programs, enabling ATEC to influence younger surgeons learning alignment-based, data-driven surgery.
  • Expansion of EOS Insight EcosystemEOS Insight provides alignment measurement, bone mineral density assessment, predictive surgical planning, patient-specific rods, and follow-up across the patient journey. ATEC also convened more than 70 leading key opinion leaders for its inaugural EOS Insight Council.
  • Valence Platform ProgressManagement said early surgeon feedback on Valence has confirmed that the platform fits naturally into the procedure, with an intuitive workflow, seamless integration, and a small physical footprint. Valence has expanded from lateral procedures to navigated TLIF, extending its indications into a posterior procedure.
  • Continued Investment in Integrated Surgical TechnologyATEC continues investing in EOS, SafeOp, and Valence to support diagnosis, surgical planning, intraoperative execution, and outcome evaluation. Management described the combination as creating a more connected surgeon experience and a broader role for ATEC before, during, and after surgery.
  • New Data Intelligence LeadershipTommy Carls joined ATEC in September as Executive Vice President, Data Intelligence and Strategy. He brings more than three decades of spine and medical technology experience and will lead efforts across EOSedge, EOS Insight, data, analytics, and informatics strategy.
  • International Commercial ProgressManagement said ATEC has gotten off to a great start in Australia, New Zealand, and Japan, with surgeon training and regulatory or society-led adoption steps progressing in those markets.
  • Stable Pricing EnvironmentManagement said pricing in the market was relatively stable in Q3, with no change from the first half of the year and no change implied for the fourth quarter.
  • Future OsteoAdapt OpportunityManagement described the biologics market as large and said early understanding and findings from the IDE suggest OsteoAdapt may have clinical advantages over BMP. ATEC expects the product to provide a significant opportunity and wants to establish a biologics foundation before its launch.
  • Updated Full-Year EBITDA Outlook Still Shows Significant GrowthDespite lower revenue expectations, ATEC expects full-year 2026 adjusted EBITDA of approximately $137 million, representing a 16% margin and approximately 47% year-over-year growth.

ATEC Earnings History

ATEC earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)0.12-0.06――
Oct 29, 20262026 (Q3)0.100.090.03200.00% (+0.06)
Aug 04, 20262026 (Q2)0.070.070.02250.00% (+0.05)
May 05, 20262026 (Q1)-0.020.00-0.11100.00% (+0.11)
Feb 24, 20262025 (Q4)0.040.06-0.03276.47% (+0.09)
Oct 30, 20252025 (Q3)-0.030.03-0.11127.78% (+0.14)
Jul 31, 20252025 (Q2)-0.040.02-0.14113.99% (+0.16)
May 01, 20252025 (Q1)-0.12-0.11-0.1838.12% (+0.07)
Feb 26, 20252024 (Q4)-0.05-0.03-0.1169.37% (+0.08)
Oct 30, 20242024 (Q3)-0.11-0.11-0.1423.40% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed